SCHEMBL1102294

SCHEMBL1102294

COc1cccc(OC)c1P(C1CCCCC1)C1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.40
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA4 P22748 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
LMNA P02545 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 2/20 0.37
HPGD P15428 1/20 0.37
POLB P06746 1/20 0.37
DRD2 P14416 1/20 0.36
DRD3 P35462 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16694832 0.98 ABCB1 (0.41) ABCB1SMN1; SMN2CA12CA1CA2
SCHEMBL16626228 0.93 ABCB1 (0.39) ABCB1SMN1; SMN2LMNANPSR1SIGMAR1
SCHEMBL17240346 0.91 ABCB1 (0.37) ABCB1SMN1; SMN2CA12CA1CA2
SCHEMBL11954834 0.91 ABCB1 (0.40) ABCB1SMN1; SMN2LMNANPSR1SIGMAR1
SCHEMBL17244833 0.89 ABCB1 (0.38) ABCB1SMN1; SMN2CA12CA1CA2
SCHEMBL2709792 0.87 HPGD (0.42) ABCB1SMN1; SMN2LMNAHPGDPOLB
SCHEMBL17529732 0.85 ABCB1 (0.46) ABCB1SMN1; SMN2CA12CA1CA2
SCHEMBL21331833 0.85 HTR1A (0.41) ABCB1SMN1; SMN2CA1CA2CA7
SCHEMBL21331777 0.85 SMN1; SMN2 (0.43) ABCB1SMN1; SMN2LMNAHPGD
SCHEMBL16162353 0.83 GAA (0.42) ABCB1SMN1; SMN2LMNASIGMAR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114270556-B Organic photoelectric conversion material 住友化学株式会社 2024-03-29 CN disclosed
CN-110741028-B Method for producing polymer compound 住友化学株式会社 2022-05-03 CN disclosed
CN-114270556-A Organic photoelectric conversion material 住友化学株式会社 2022-04-01 CN disclosed
EP-2990113-B1 METHOD FOR PRODUCING CATALYST FOR CYCLIC CARBONATE SYNTHESIS MARUZEN PETROCHEM CO LTD (JP) 2020-03-25 EP disclosed
EP-2990112-B1 METHOD FOR MANUFACTURING CATALYST FOR SYNTHESIZING CYCLIC CARBONATE MARUZEN PETROCHEM CO LTD (JP) 2020-03-25 EP disclosed
US-10029241-B2 Method for producing catalyst for cyclic carbonate synthesis MARUZEN PETROCHEMICAL CO., LTD. (JP) 2018-07-24 US disclosed
US-10011621-B2 Method for producing silica gel-immobolized phosphonium salt catalysts MARUZEN PETROCHEMICAL CO., LTD. (JP) 2018-07-03 US disclosed
US-9834536-B2 Method for producing catalyst for cyclic carbonate synthesis NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2017-12-05 US disclosed
WO-2017093149-A1 Process for the Catalytic Reversible Alkene-Nitrile Interconversion STUDIENGESELLSCHAFT KOHLE MBH (DE) 2017-06-08 WO disclosed
EP-2492274-B1 2,4,6- OR 2,6-ALKOXYPHENYL DIALKYLPHOSPHINE, TETRAFLUOROBORATE AND USE THEREOF UNIV ZHEJIANG (CN) 2016-09-21 EP disclosed
US-20090221820-A1 Ligands for Transition-Metal-Catalyzed Cross-Couplings, and Methods of Use Thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2009-09-03 US disclosed
US-20090221820-A1 Ligands for Transition-Metal-Catalyzed Cross-Couplings, and Methods of Use Thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2009-09-03 US disclosed
WO-2009085185-A1 FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS AMGEN INC. (US) 2009-07-09 WO disclosed
WO-2009076622-A2 LIGANDS FOR TRANSITION-METAL-CATALYZED CROSS-COUPLINGS, AND METHODS OF USE THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2009-06-18 WO disclosed
US-20090099173-A1 Pyridopyridazine compounds, compositions and methods of use AMGEN INC. (US) 2009-04-16 US disclosed
US-20090099173-A1 Pyridopyridazine compounds, compositions and methods of use AMGEN INC. (US) 2009-04-16 US disclosed
WO-2009035568-A1 ANNELATED PYRIDAZINES FOR THE TREATMENT OF TUMORS DRIVEN BY INAPPROPRIATE HEDGEHOG SIGNALLING AMGEN INC. (US) 2009-03-19 WO disclosed
US-20090048259-A1 Phthalazine compounds, compositions and methods of use AMGEN INC. (US) 2009-02-19 US disclosed
US-20090048259-A1 Phthalazine compounds, compositions and methods of use AMGEN INC. (US) 2009-02-19 US disclosed
WO-2009002469-A1 PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048259-A1 Phthalazine compounds, compositions and methods of use VHL, HDAC5, SUZ12 ABCB1 351/4885SMN1; SMN2 2098/4885CA12 154/4885
US-20090099173-A1 Pyridopyridazine compounds, compositions and methods of use DPYD, CYP3A5, PNPO ABCB1 49/4885SMN1; SMN2 1941/4885CA12 1899/4885
US-10029241-B2 Method for producing catalyst for cyclic carbonate synthesis CYCS, CA7, CA9 ABCB1 4857/4885SMN1; SMN2 4667/4885CA12 5/4885
US-10011621-B2 Method for producing silica gel-immobolized phosphonium salt catalysts SIK2, SIK3, SIK1 ABCB1 3878/4885SMN1; SMN2 4562/4885CA12 252/4885
US-20090221820-A1 Ligands for Transition-Metal-Catalyzed Cross-Couplings, and Methods of Use Thereof SOD1, TIMCC, TST ABCB1 4560/4885SMN1; SMN2 3652/4885CA12 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.